News 
Market Data 
Discover
I usually have a lot to say. I just know when to keep it to myself.
lady*b
I usually have a lot to say. I just know when to keep it to myself.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I usually have a lot to say. I just know when to keep it to myself.
KRY (3.91) AMEX- Crystallex Updates Shareholders Regarding Permitting for the Las Cristinas Gold Project
Thursday June 14, 7:56 am ET
TORONTO, ONTARIO--(MARKET WIRE)--Jun 14, 2007 -- Crystallex International Corporation (Toronto:KRY.TO - News)(AMEX:KRY - News) reported today it has received notice from the Corporacion Venezolana de Guayana ("CVG"), that the requirements of the Ministry of the Environment and Natural Resources of Venezuela ("MinAmb" formerly referred to as "MARN") for the issuance of the Environmental permit to commence construction of the Las Cristinas Project have been fulfilled.
MinAmb, based on its approval of the Environmental Impact Study ("EIS") for the Las Cristinas gold project, requested the CVG to post a Compliance Guarantee Bond and pay certain taxes for the issuance of the Environmental permit. Crystallex has posted the bond and paid the taxes.
The CVG confirmed that the approval of the EIS, the posting of the bond and the payment of the taxes represent the final and conclusive step in the procedure for the issuance of the Environmental permit to construct the Las Cristinas Project. Crystallex as the builder and operator of Las Cristinas will have use of this permit in order to construct the project on the basis of the approved feasibility study.
In the formal notice that MinAmb sent to the CVG, it was stated that the Environmental permit will be issued following the payment of taxes and posting of the bond. The CVG now awaits the permit required for the construction of the mine from MinAmb.
Mr. Gordon Thompson, Crystallex President and CEO commented, "The request by the Venezuelan Government for the posting of the Compliance Guarantee Bond and taxes further confirms our understanding that we've complied with the very final stage of the procedure for receipt of the environmental permit."
About Crystallex
Crystallex International Corporation is a Canadian based gold producer with significant operations and exploration properties in Venezuela. The Company's principal asset is the Las Cristinas property in Bolivar State that is currently under development and which is expected to commence gold production in 2009 at an initial annualized rate of some 300,000 ounces at the initial planned production rate of 20,000 tonnes of ore per day. Other key assets include the Tomi Mine, certain Lo Increible properties and the Revemin Mill. Crystallex shares trade on the TSX (symbol: KRY) and AMEX (symbol: KRY) Exchanges.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws, including: statements relating to the estimated reserves and resources at Las Cristinas; anticipated results of drilling programs, feasibility studies or other analyses; the potential to increase reserves and expand production, at Las Cristinas; Crystallex's projected construction and production schedule, and cost and production estimates, for Las Cristinas; and management's statements regarding its expectations regarding mining in Venezuela. Forward-looking statements are based on estimates and assumptions made by Crystallex in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that Crystallex believes are appropriate in the circumstances. Many factors could cause Crystallex's actual results, performance or achievements to differ materially from those expressed or implied by the forward looking statements, including: gold price volatility; impact of any hedging activities, including margin limits and margin calls; discrepancies between actual and estimated production, between actual and estimated reserves, and between actual and estimated metallurgical recoveries; mining operational risk; regulatory restrictions, including environmental regulatory restrictions and liability; risks of sovereign investment; speculative nature of gold exploration; dilution; competition; loss of key employees; additional funding requirements; and defective title to mineral claims or property. These factors and others that could affect Crystallex's forward-looking statements are discussed in greater detail in the section entitled "Risk Factors" in Crystallex's Annual Information Form (which is included in the Annual Report on Form 40-F that Crystallex files with the United States Securities and Exchange Commission (the "SEC") and elsewhere in documents filed from time to time with the Canadian provincial securities regulators, the SEC and other regulatory authorities. These factors should be considered carefully, and persons reviewing this press release should not place undue reliance on forward-looking statements. Crystallex has no intention and undertakes no obligation to update or revise any forward-looking statements in this press release, except as required by law.
Contact:
Contacts:
Investor Relations Contact:
Crystallex International Corporation
Richard Marshall, VP
1-800-738-1577
Email: info@crystallex.com
Website: http://www.crystallex.com
--------------------------------------------------------------------------------
Source: Crystallex International Corporation
http://biz.yahoo.com/iw/070614/0266210.html
**IDIX (7.23) Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
Tuesday June 12, 7:00 am ET
~ Valopicitabine achieved both primary and secondary endpoints of study; no negative drug-drug interaction was observed between valopicitabine and ribavirin ~
CAMBRIDGE, Mass., June 12 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX - News) today announced results from a phase II study designed to evaluate triple combination therapy, consisting of valopicitabine (NM283), Idenix's lead drug candidate for the treatment of hepatitis C, pegylated interferon and ribavirin compared to pegylated interferon and ribavirin, the current standard of care, in patients infected with the genotype-1 strain of the hepatitis C virus (HCV). This study demonstrated no pharmacokinetic or pharmacodynamic drug-drug interaction between valopicitabine and ribavirin. The triple combination showed consistently higher rates of HCV PCR-negativity, defined as serum HCV RNA levels below 20 copies/mL, compared to the standard of care at every point analyzed in this study. Additionally, the tolerability of the triple combination was satisfactory, with only three discontinuations from the study.
"I am very encouraged to observe this degree of viral clearance coupled with a very low rate of discontinuations in patients treated with the triple combination of valopicitabine, pegylated-interferon and ribavirin in this study," said Dr. Fred Poordad, Chief of Hepatology and Liver Transplantation, Cedars Sinai Medical Center, and an investigator in this study. "These data represent an important achievement in the development of novel HCV combination therapy."
Study Design and Results
The three-arm, partially blinded, randomized study enrolled 117 treatment- naive, HCV genotype-1 infected patients at approximately 20 centers in the United States. Patients in arm A (n=39) received 200 mg/day of valopicitabine and pegylated interferon alpha 2a; patients in arm B (n=39) received 200 mg/day of valopicitabine, weight-based dosing of ribavirin, and pegylated interferon alpha 2a; and patients in arm C (n=39) received placebo, weight- based dosing of ribavirin and pegylated interferon alpha 2a. For all patients in this study there was a seven day lead-in period, where patients received either valopicitabine or placebo alone; the additional components of each arm's therapeutic regimen were administered beginning on day eight.
The primary endpoint of the study was to assess pharmacokinetic and pharmacodynamic drug-drug interaction between valopicitabine and ribavirin after 36 days of treatment. Drug levels for both NM107 (the active form of valopicitabine) and ribavirin when administered alone or together were within the range of 80 to 125 percent, indicating the lack of an interaction. At day 36, 23 percent of patients treated with triple combination therapy (arm B) were HCV PCR-negative per protocol, compared to 11 percent of patients treated with the standard of care (arm C) and 14 percent of patients treated with valopicitabine and pegylated interferon (arm A). These findings demonstrated no pharmacokinetic or pharmacodynamic drug-drug interaction between valopicitabine and ribavirin.
The key secondary endpoints for the study were antiviral activity, safety and tolerability at 12 weeks. Of patients that completed 12 weeks of therapy, 72.2 percent of patients treated with triple combination therapy (arm B) achieved HCV PCR-negativity, compared to 61.5 percent of patients treated with the standard of care (arm C). There were three discontinuations from the study, all due to adverse events (AEs), one of which was attributed by the clinical investigator to valopicitabine-related gastrointestinal toxicity. The two other AEs, including a serious adverse event (SAE), were attributed by the clinical investigators to pegylated interferon or pegylated interferon/ribavirin. All of the discontinuations occurred in the triple combination arm (arm B).
At the end of 12 weeks, patients were permitted to roll over to pegylated interferon plus ribavirin for up to 48 weeks of total treatment; all eligible patients elected to do so.
"These results support our hypothesis that valopicitabine can be administered in combination with pegylated interferon and ribavirin," said Douglas Mayers, M.D., executive vice president and chief medical officer of Idenix Pharmaceuticals. "We are very pleased with the viral kinetics and HCV RNA clearance rates observed in patients treated with triple combination therapy in this study and look forward to further development of this combination."
About Valopicitabine
Valopicitabine is an investigational nucleoside polymerase inhibitor being evaluated in ongoing clinical trials for the treatment of hepatitis C. The most common adverse events reported in valopicitabine clinical trials to date include nausea, vomiting, fatigue, diarrhea, headache, flu-like symptoms and depression. Idenix is developing valopicitabine in collaboration with Novartis Pharma AG.
About Hepatitis C
HCV infection is the most common chronic blood-borne infection in the United States.(1) The Centers for Disease Control and Prevention estimates that 4 million Americans have been infected with HCV, and 2.7 million of these carry chronic HCV infections.(2) Hepatitis C-related liver failure is the most common indication for liver transplantation in the United States.(2) As the prevalence of severe liver disease attributable to hepatitis C rises, deaths due to complications from hepatitis C infection, currently 8,000 to 10,000 per year in the United States, are increasing and are expected to triple by 2010.(3)
Conference Call Information
Idenix will hold a conference call today at 8:30 a.m. EDT. To access the call please dial (800) 774-5358 U.S./Canada or (706) 758-9475 International and enter passcode 3143678 or to listen to a live webcast of the call, go to "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 10 minutes before the call to ensure a timely connection. A replay of the conference call and webcast will be available until June 26, 2007. To access the replay, please dial (800) 642-1687 U.S./Canada or (706) 645-9291 International and enter the passcode 3143678.
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.
Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements can be identified by the use of forward-looking terminology such as "will," "can be," "expect," "anticipates," "advance," "significant achievement," "pending," "encouraging," "believe," or similar expressions and implied statements with respect to the regulatory success of valopicitabine or the Idenix clinical development program in hepatitis C, or any potential pipeline candidates and expectations with respect to the size of the market for Hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by unexpected regulatory actions or delays; results of clinical trials, including additional data relating to the ongoing or future clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; the ability of the company to attract and retain qualified personnel; competition in general; the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries and the Company's ability to accurately assess the market. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2006 and filed with the Securities and Exchange Commission, the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 and other filings that the company makes with the Securities and Exchange Commission.
All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.
(1) Center For Disease Control National Prevention Strategy.
(2) Center for Disease Control. Hepatitis C Fact Sheet accessed online at http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm.
(3) Davis, G. et al., Projecting Future Complications of Chronic Hepatitis C in the United States. Liver Transplantation, April 2003.
Idenix Pharmaceuticals' Contacts:
Media: Teri Dahlman (617) 995-9905
Investors: Amy Sullivan (617) 995-9838
--------------------------------------------------------------------------------
Source: Idenix Pharmaceuticals, Inc.
http://biz.yahoo.com/prnews/070612/netu006.html?.v=10
TYL (12.16) NYSE: Tyler Technologies Signs Contract With State of Indiana to Provide Odyssey Courts Software Statewide
Monday June 11, 8:03 am ET
Shares Outstanding: 38.94M
Float: 36.58M
DALLAS, June 11 /PRNewswire-FirstCall/ -- Tyler Technologies, Inc. (NYSE: TYL - News) announced today that the Indiana Supreme Court has signed a contract for Tyler to provide and implement its Odyssey software to manage cases for Indiana trial courts. The contract, which followed a lengthy competitive procurement and includes software licensing and professional services for training and deployment, is valued at approximately $11 million, with additional services expected to be added later through follow-on agreements.
"With more than 1.5 million cases filed in Indiana courts each year, Hoosier law enforcement officers, lawyers, government agencies and citizens need timely and accurate court information. Indiana courts and court clerks must have a 21st century computer system to help them manage their caseloads and provide court information to those who need it. While many individual courts have computerized case management systems today, we believe Tyler offers us the best opportunity to equip Indiana courts with a 21st century case management system and to connect those systems with each other and with those who need and use court information," said Justice Frank Sullivan, Jr., chair of the Supreme Court's Judicial Technology and Automation Committee (JTAC).
Odyssey is Tyler's new generation Web-based court case management solution for the state and local government market. A unified case management system as defined by the National Center for State Courts, Tyler's Odyssey system enables courts to automate all case management functions -- imaging, accounting, docketing, calendaring, reporting, forms merge and others -- for all case types, in a single software package. Tyler's Odyssey system is currently deployed statewide in Minnesota and New Hampshire, and eight of the nation's 35 largest counties have signed contracts with Tyler to implement Odyssey.
"We are extremely pleased that the Indiana Supreme Court has chosen to implement Tyler's Odyssey Case Manager solution statewide," commented Dustin Womble, Executive Vice President of Tyler Technologies. "The Court conducted an extremely thorough evaluation of competing courts software products, and Tyler emerged as the clear choice. We look forward to continuing to build what we believe will be a long and mutually rewarding partnership between Tyler and the state of Indiana. In our view, Odyssey is now firmly established as the courts software market leader, and our combination of advanced technology, deep domain expertise, and strong client references from across the nation enables us to continue to build momentum in the courts marketplace."
The Indiana Supreme Court's selection of Tyler to provide new case management software completed months of review of 14 proposals submitted by vendors from throughout the country in response to a public solicitation in early 2006. The selection process included week-long product demonstrations in Indianapolis by finalist vendors, including demonstrations open to the public. More than 175 individuals attended these public sessions. Indiana judges, clerks and other experts also traveled to courts in Indiana and other states where finalist vendors' systems were in use.
The Court's choice of Tyler's Odyssey product adopted the recommendation made by both JTAC and a statewide board of judges, clerks, court staff and technology experts established by JTAC to oversee and govern the computerized case management system project. Judge John A. Rader of the Warren Circuit Court noted that he and his fellow statewide board members Judge Mary G. Willis of the Henry Circuit Court, and Judge Frances C. Gull of the Allen Superior Court, had spent "countless hours in product demonstrations, systems review, and speaking to actual court end users. All three of us were strongly of the opinion that the Tyler Odyssey product was the top choice for Indiana courts." Judge Rader added that his, Judge Willis', and Judge Gull's extensive involvement "insured that the selection of Tyler reflected the informed views of sitting judges from small, medium and large Indiana counties."
Judge Gull said that she appreciated the Supreme Court's adoption of the statewide board's recommendation because she had "personally visited judges, clerks and court staff using each of the competing vendors' products," and believed the selection of Tyler was "the right choice for Indiana." Another member of the statewide board, Al Mizen, the chief financial officer of Center Township in Marion County, added that "among the vendors we examined, Tyler had the best technology for connecting court computer systems with those of state agencies such as the Bureau of Motor Vehicles, the Department of Revenue, and law enforcement agencies."
Two county clerks who participated in the procurement also endorsed the selection of Tyler and its Odyssey product. "The Odyssey case management system provided the best combination of functionality, technology, usability, and a proven track record for implementing statewide trial court case management systems," said Therese Brown, Allen County Clerk. "While not perfect, having personally seen the system in use in Minnesota and comparing it with other case management products, I believe that Tyler's system will be the best for Indiana's courts and clerks," added Jackie Rowan, DeKalb County Clerk.
Based in Dallas, Tyler Technologies is a leading provider of end-to-end information management solutions and services for local governments. Tyler partners with clients to make local government more accessible to the public, more responsive to needs of citizens, and more efficient. Tyler's client base includes more than 6,000 local government offices throughout all 50 states, Canada, Puerto Rico and the United Kingdom. In April 2007, Tyler was named one of "America's 100 Most Trustworthy Companies" by Audit Integrity, an independent research firm. More information about Tyler Technologies can be found at http://www.tylertech.com.
Tyler Technologies, Inc. has included in this press release "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 concerning its business and operations. Tyler Technologies expressly disclaims any obligation to release publicly any updates or revisions to these forward-looking statements to reflect any change in its expectations. These expectations and the related statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties which forward-looking statements are subject to include, but are not limited to, changes in competition, changes in general economic conditions, changes in the budgets and regulatory environments of the Company's customers, risks associated with the development of new products and the enhancement of existing products, the ability to attract and retain qualified personnel, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Tyler Technologies, Inc.
SINA (39.14) SINA, Google Team Up to Provide Superior Search Experience to Chinese Users
Monday June 11, 6:10 am ET
SHANGHAI, China, June 11 /Xinhua-PRNewswire/ -- SINA Corporation, a leading internet portal in China, and Google, the world's largest search engine company, announced today a strategic partnership in the areas of search, advertisement and news, in an effort to provide better search experience to Internet users in China.
Under the strategic partnership, Google's web page search service will be embedded in SINA's search box, allowing users to easily and conveniently switch between online content and web page search. In the area of advertising cooperation, advertisers on SINA will be able to maximize their brand value, leveraging SINA's large traffic and Google's proven online advertising system and experience. Through this cooperation, SINA will increase its influence among Chinese portal users, and Google will continue to popularize its brand, products and services in China. In the near future, Google and SINA will expand their cooperation into news and other content areas to provide Chinese users with an ever improving search experience.
"This partnership leverages the strong offerings of two Internet powerhouses to provide Internet users in China a better overall experience," said Mr. Charles Chao, CEO of SINA. "Google search is the most popular search engine in the world and we would like our large user base to enjoy the experience. SINA is the leading internet portal in China and SINA News is one of the most popular online sources for news in China. We are pleased that this cooperation will make SINA News even more easily accessible by more users. Through our strategic cooperation, online users as well as online advertisers stand to benefit from the leveraging of strong brands, traffic and technologies from the two companies. We believe this partnership will allow us to explore more opportunities for cooperation in the future."
"SINA is the most influential portal in China and a household brand in China's Internet industry," said Dr. Kai-Fu Lee, Vice President of Google and President of Google Greater China. "Google's mission is to organize the world's information and make it universally accessible and useful. Google focuses on meeting local user needs in China and is committed to providing Chinese users with the best products and services. The strategic partnership with SINA is just another example of Google's continuous localization efforts in China. The comprehensive cooperation will combine our resources and give full play to our respective advantages. With it, we will be able to provide more Chinese users with superior experience in search and news, and assist Chinese enterprises grow their businesses."
About SINA
SINA Corporation (Nasdaq: SINA - News) is a leading online media company and value-added information service (VAS) provider for China and for global Chinese communities. With a branded network of localized web sites targeting Greater China and overseas Chinese, SINA provides services through five major business lines including SINA.com (online news and content), SINA Mobile (mobile value-added services), SINA Community (community-based services and games), SINA.net (search and enterprise services) and SINA E-Commerce (online shopping). Together these provide an array of services including region- focused online portals, mobile value-added services, search and directory, interest-based and community-building channels, free and premium email, online games, virtual ISP, classified listings, fee-based services, e-commerce and enterprise e-solutions.
About Google
Google Inc. ( http://www.google.com ) has innovative search technologies that are providing information services to millions of users around the world. Google is a leader in all major markets of the Internet industry. Google offers targeted advertisement services with measurable results for enterprises of all sizes, with enhanced experiences for Internet users. Google has its headquarters in Silicon Valley, with offices across North America, Europe and Asia.
Safe Harbor Statement
This announcement contains forward-looking statements that relate to, among other things, SINA's strategic and operational plans. SINA may also make forward-looking statements in the Company's periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in its proxy statements, in its offering circulars and prospectuses, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. SINA assumes no obligation to update the forward-looking statements in this release and elsewhere. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward- looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, SINA's limited operating history, the uncertain regulatory landscape in the People's Republic of China, the changes by mobile operators in China to their policies for MVAS, the Company's ability to develop and market other MVAS products, fluctuations in quarterly operating results, the Company's reliance on online advertising sales and MVAS for a majority of its revenues, the Company's reliance on mobile operators in China to provide MVAS, any failure to successfully develop and introduce new products and any failure to successfully integrate acquired businesses. Further information regarding these and other risks is included in SINA's Annual Report on Form 10-K for the year ended December 31, 2006 and its other filings with the Securities and Exchange Commission.
For more information, please contact:
Cathy Peng
SINA Investor Relations
Tel: +86-10-6262-8888 x3112
Email: ir@staff.sina.com.cn
David Pasquale
The Ruth Group
Tel: +1-646-536-7006
Email: dpasquale@theruthgroup.com
--------------------------------------------------------------------------------
Source: SINA Corporation
http://biz.yahoo.com/prnews/070611/cnm019.html?.v=8
NWPX (33.52) Northwest Pipe Company Announces $8M Order
Monday June 11, 5:00 am ET
Shares Outstanding: 8.93M
Float: 8.60M
PORTLAND, OR--(MARKET WIRE)--Jun 11, 2007 -- Northwest Pipe Company (NasdaqGS:NWPX - News) reported today that it was named as pipe supplier by Garney Construction Company of Kansas City, Missouri for a water transmission pipeline for Johnson County Water District.
The Company will supply approximately 28,000 feet of steel pipe valued at approximately $8 million for an engineered and custom fabricated piping system. The pipe is expected to be manufactured in the Company's Denver, Colorado division with delivery scheduled to begin in the fourth quarter of 2007.
Northwest Pipe Company manufactures welded steel pipe in three business segments. Its Water Transmission Group is a leading supplier of large diameter, high-pressure steel pipe products that are used primarily for water infrastructure in North America. Its Tubular Products Group manufactures smaller diameter steel pipe for a wide range of construction, agricultural, energy, industrial and mechanical applications. Its Fabricated Products Group manufactures propane tanks and other fabricated products. The Company is headquartered in Portland, Oregon and has nine manufacturing facilities across the United States and Mexico.
This release contains forward-looking statements, including but not limited to those regarding the project described above. These statements reflect management's current views and estimates of market circumstances, industry conditions and Company performance. Actual results could vary materially from the description contained herein due to many factors including market demand, operating efficiencies, availability and price of raw materials, and other risks described from time to time in the Company's reports to the Securities and Exchange Commission.
Source: Northwest Pipe Company
http://biz.yahoo.com/iw/070611/0264029.html
ERIC: Chart:
AI
